FCS Hematology Oncology Review
It is because of the extensive research conducted through clinical studies that we have the privilege of providing world class cancer care to our patients. We are fortunate to partner with one of the world’s leading cancer research organizations, Sarah Cannon, to bring over 300 clinical trials to our patients each year. Many of these studies have gone on to become the majority of new FDA approved cancer treatments available to patients today.
Additionally, our physicians are acutely aware of the research being conducted outside of Florida Cancer Specialists & Research Institute (FCS), as it too, carries a profound impact on the care we provide our patients. The FCS Clinical Review is a collection of many studies or articles from the leading oncology physicians across the globe, providing a platform for our physicians to continue exploring how we can continue to advance the care we provide.
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial
This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS).
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)
Distant metastases are present in 6% or more of patients with newly diagnosed breast cancer. In this context, locoregional therapy for the intact primary tumor has been hypothesized to improve overall survival (OS), but clinical trials have reported conflicting results.
Association of Daily Sitting Time and Leisure-Time Physical Activity With Survival Among US Cancer Survivors
What are the independent and joint associations of daily sitting time and physical activity with mortality outcomes among cancer survivors in the US?